Pediatrix Medical Group, Inc. (MD) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. Pediatrix Medical Group, Inc. is a leading provider of physician services, including neonatal, maternal-fetal, and pediatric subspecialty care, operating across 37 states. The company has recently completed a strategic shift to exit almost all affiliated office-based practices (completed by Q4 2024) to focus on hospital-based and maternal-fetal medicine services.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Net Revenue | $492.9 million | $511.2 million | $1.42 billion | $1.51 billion |
| Net Income | $71.7 million | $19.4 million | $131.7 million | ($129.5 million) |
| Diluted EPS | $0.84 | $0.23 | $1.54 | ($1.56) |
| Operating Margin | 13.8% | 6.6% | 11.3% | (7.1)% |
| Adjusted EBITDA | $87.3 million | $60.2 million | $209.7 million | $155.3 million |
| Cash & Equivalents | $340.1 million | $103.8 million | $340.1 million | $103.8 million |
| Working Capital | $324.6 million | $205.5 million | $324.6 million | $205.5 million |
| Total Debt (Principal) | $601.6 million | $601.6 million | $601.6 million | $601.6 million |
Note: Total Debt includes $400.0 million in 2030 Notes and $201.6 million in Term A Loan. No balance on Revolving Credit Line.
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased 3.6% in Q3 and 6.0% YTD compared to 2024. This decline is primarily due to the exit of office-based practices and primary/urgent care service lines in 2024. However, same-unit revenue increased by 8.0% in Q3 and 6.9% YTD, driven by improved collections, higher patient acuity (neonatology), and favorable payor mix shifts.
- Profitability Surge: Net income turned from a loss of $129.5 million YTD 2024 to a profit of $131.7 million YTD 2025. The 2024 loss was heavily impacted by a $154.2 million goodwill impairment and $27.8 million in long-lived asset impairments, which were absent in 2025.
- Expense Reduction: Practice salaries and benefits decreased 8.9% in Q3 and 9.1% YTD, largely due to practice dispositions. Restructuring expenses dropped significantly from $40.6 million YTD 2024 to $16.4 million YTD 2025.
- One-Time Gains: Q3 2025 included a $20.9 million net gain on investments in divested businesses (cash proceeds of $30 million from the sale of an investment in a divested management services organization).
Guidance, Outlook, and Risks
- Strategic Focus: Management continues to optimize the portfolio, focusing on hospital-based neonatal and maternal-fetal medicine services. The company exited its primary and urgent care service line in 2024.
- Regulatory Environment: The company faces risks related to the "No Surprises Act" (NSA) and potential changes to Medicaid reimbursement following the "One Big Beautiful Bill Act" signed in July 2025, which imposes work requirements and increases cost-sharing. These could impact reimbursement rates.
- Liquidity: The company maintains strong liquidity with $340.1 million in cash and $450.0 million available on its revolving credit line. Management believes funds are sufficient for operations, acquisitions, and share repurchases for the next 12 months.
- Share Repurchases: In August 2025, the Board authorized a new $250 million repurchase program. The company repurchased 1.2 million shares for $20.9 million in Q3 2025.
- Legal Contingencies: The company is subject to routine government audits and medical malpractice claims. While no accrual is currently made for potential liabilities, unfavorable outcomes could have a material adverse effect.
Investor Verification Checklist
- Same-Unit Growth Sustainability: Verify if the 8.0% same-unit revenue growth is sustainable given the exit of lower-margin office-based practices.
- Reimbursement Rates: Monitor the impact of the "One Big Beautiful Bill Act" and NSA on Medicaid and commercial reimbursement rates, particularly for out-of-network services.
- Debt Covenants: Confirm continued compliance with the Amended Credit Agreement covenants (interest coverage and net leverage ratios) as the company manages its $601.6 million debt load.
- Professional Liability Reserves: Review the adequacy of the $269.2 million professional liability reserve, given the company self-insures a portion of this risk.
- Acquisition Integration: Assess the integration and performance of the $19.2 million acquisition of neonatology and maternal-fetal practices completed in September 2025.